

National COVID-19 Vaccine Program (NCVP) Dashboard – April 2024

Delivery Confidence: Med/High

Trending: GREEN

Overall Program Status: GREEN

Maintaining Critical NCVP elements

Senior Responsible Officer: Anna Peatt

s 22


Vaccine Supply Workstream:

- Vaccines remain in a surplus of supply to approximately mid-2026.
- Forecasted supply gaps of Novavax s22 vaccines are currently being managed with healthcare professionals, with supply of Novavax anticipated to resume in early 2025 and s22 subject to regulatory approvals s22.
- Negotiations are underway with manufacturers to secure the most updated vaccines in the latest presentations i.e. JN.1 vaccines (On 26 April 2024, WHO recommend switch to JN.1 strain) and pre-filled syringes for supply in Q4 2024 s22, subject to regulatory approval.

s22

s 22

Tier 1 - National COVID-19 Vaccine Program (NCVP) Roadmap



Please note that the NCVP Roadmap is a dynamic document subject to frequent updates, developed to manage milestones for the critical program elements and dependencies across the future program.